| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +1.43M | 100% | $2.21 | +$3.16M |
| Sells | 0 | ||||
| Net | +1 | +1.43M | 100% | +$3.16M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| R.A. Session II | 10%+ Owner | $14.7M | Jul 12, 2023 | ||
| Paul B. Manning | 10%+ Owner | $13.9M | +$3.16M | +29.5% | Jun 27, 2024 |
| Audentes Therapeutics, Inc. | 10%+ Owner | $11.8M | Oct 21, 2022 | ||
| Sean P. Nolan | Chief Executive Officer, Director | $4.44M | Jan 2, 2024 | ||
| John A. Stalfort III | Director | $2.99M | May 29, 2024 | ||
| Sukumar Nagendran | President and Head of R&D, Director | $1.46M | Jan 2, 2024 | ||
| Kamran Alam | Chief Financial Officer | $1.27M | Feb 2, 2024 | ||
| Suyash Prasad | CMO and Head of R&D | $865K | Jul 5, 2022 | ||
| Phillip B. Donenberg | Director | $247K | May 29, 2024 | ||
| Alison S. Long | Director | $74.3K | May 29, 2024 | ||
| Laura Sepp-Lorenzino | Director | $74.3K | May 29, 2024 | ||
| Kathleen Reape | Director | Jun 22, 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|